NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Co-author Dr. Jian L. Campian, of Washington University and Siteman Cancer Center and member of the Steering Committee:

“The overall patient population in the trial appears to live longer than we would typically see with current standard of care, and 30% of the patients have lived much longer than we would expect, given the typical course of this cancer,” Dr. Campian said.

“In general, patients with this cancer live 15 to 17 months. The surprising part was that the 100 ‘extended survivors’ don’t appear to have the usual characteristics associated with a good prognosis. We are continuing to study these patients to understand why they have done so well.”

http://www.sci-news.com/medicine/personalized-vaccine-glioblastoma-06062.html